CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Wall Street sentiment is positive on CAMP4 Therapeutics, with nine analysts giving it an average rating of “Moderate Buy.” Seven analysts rate it a buy, while two rate it a sell, and the average price target is about $8.36.
• The stock fell 7.4% in the latest session and was trading at $3.90, well below its 12-month high of $7.75. CAMP4 has a market cap of about $202.5 million and has traded between $1.32 and $7.75 over the past year.
• The company’s latest earnings report was weak, with EPS of -$0.32 versus expectations of -$0.21 on revenue of $1.29 million. Analysts currently expect CAMP4 to post a full-year EPS of -0.84.

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $8.3571.

Several brokerages recently issued reports on CAMP. Leerink Partners increased their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an "outperform" rating in a report on Thursday, April 2nd. Zacks Research lowered CAMP4 Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Wednesday. Weiss Ratings downgraded CAMP4 Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, May 21st. Rodman & Renshaw assumed coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a "buy" rating and a $7.00 price target for the company. Finally, JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a "neutral" rating to an "overweight" rating and increased their price objective for the stock from $5.00 to $9.00 in a report on Tuesday, June 16th.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several hedge funds have recently bought and sold shares of the business. Vivo Capital LLC acquired a new position in CAMP4 Therapeutics during the third quarter worth $11,765,000. Balyasny Asset Management L.P. acquired a new stake in shares of CAMP4 Therapeutics in the fourth quarter worth about $14,938,000. Janus Henderson Group PLC lifted its position in shares of CAMP4 Therapeutics by 35.9% in the fourth quarter. Janus Henderson Group PLC now owns 6,307,636 shares of the Wireless communications provider's stock worth $38,807,000 after buying an additional 1,666,666 shares during the last quarter. SummitTX Capital L.P. bought a new stake in shares of CAMP4 Therapeutics during the 1st quarter worth about $1,497,000. Finally, EcoR1 Capital LLC bought a new stake in shares of CAMP4 Therapeutics during the 4th quarter worth about $1,992,000.

CAMP4 Therapeutics Stock Down 7.4%

CAMP stock opened at $3.90 on Friday. CAMP4 Therapeutics has a 12-month low of $1.32 and a 12-month high of $7.75. The company has a market cap of $202.53 million, a price-to-earnings ratio of -1.65 and a beta of 0.10. The company has a 50 day moving average of $4.28 and a two-hundred day moving average of $4.56.

CAMP4 Therapeutics (NASDAQ:CAMP - Get Free Report) last issued its earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.11). CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. The company had revenue of $1.29 million for the quarter. On average, research analysts anticipate that CAMP4 Therapeutics will post -0.84 EPS for the current year.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.